Repatha

Repatha (evolocumab) is an injectable biologic medication that powerfully lowers LDL cholesterol ("bad cholesterol") and reduces the risk of heart attacks, strokes, and coronary revascularization. Approved in 2015, it belongs to the class of PCSK9 inhibitors — a transformative advance in cholesterol management for patients who cannot reach LDL goals on statins alone, or who are statin-intolerant.

Repatha belongs to the PCSK9 Inhibitors class of medications. Evolocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, Repatha increases the number of LDL receptors available to clear LDL from the bloodstream, lowering LDL-C by 50–70% on top of statin therapy. Understanding this mechanism clarifies why Repatha is so effective and why it works best when combined with maximally tolerated statin therapy.

## What Repatha is used for

Repatha is prescribed for Primary hyperlipidemia (LDL-C lowering), Cardiovascular risk reduction, Homozygous familial hypercholesterolemia, and Heterozygous familial hypercholesterolemia. It is used in adults with established cardiovascular disease or familial hypercholesterolemia who need additional LDL lowering beyond what statins and other oral agents achieve. Repatha is available by prescription only and has been FDA-authorized since 2015.

## Dosage and administration

Typical adult dosing: Primary hyperlipidemia/CV risk reduction: 140 mg SC every 2 weeks OR 420 mg SC once monthly.

Repatha offers dosing flexibility: 140 mg every two weeks (one injection) or 420 mg once monthly (using the Pushtronex device, which delivers three 140 mg injections in a single application). Both regimens achieve similar LDL reduction. Injection sites are rotated among the abdomen, thigh, and upper arm. Allow the autoinjector to reach room temperature before use. Never change your dose or stop Repatha without speaking to your prescriber.

## Side effects

Common side effects include Nasopharyngitis, Upper respiratory tract infection, Injection-site reactions, Back pain, and Influenza. Serious side effects include Serious allergic reactions (rare) and Neurocognitive effects (very rare; under investigation). Repatha is generally very well tolerated. The most common side effects are mild infections and injection-site reactions. Rare hypersensitivity reactions, including rash and urticaria, have been reported. The FOURIER cardiovascular outcomes trial and long-term extension data confirm Repatha's safety profile at both standard doses.

## Managing common side effects

• Nasopharyngitis/URI: rest, stay hydrated, and contact your clinician if symptoms worsen.
• Injection-site reactions: rotate sites, allow the autoinjector to reach room temperature, and apply gentle pressure after injection.
• Back pain: gentle stretching, heat, or over-the-counter analgesics may help; report persistent pain to your clinician.

## Warnings and precautions

Key precautions: Hypersensitivity reactions including rash, urticaria, and hypersensitivity vasculitis have been reported; Data on pregnancy are limited — use with caution and discuss with your clinician. If you develop signs of a severe allergic reaction (hives, swelling of face or throat, difficulty breathing), stop the injection and seek emergency care immediately.

## Drug interactions

Repatha has no clinically significant pharmacokinetic drug interactions. It is commonly and safely combined with statins and ezetimibe for greater LDL lowering. Keep your prescriber informed of all medications you take.

## Cost, coverage, and savings

Repatha's list price is approximately $500–$700 per month without insurance, but most commercially insured patients pay significantly less. Amgen offers the Repatha Copay Card ($0 for eligible commercially insured patients) and the Repatha PAP (patient assistance program) for uninsured patients who qualify. Searching for a repatha copay card, repatha savings card, or repatha patient assistance at amgen.com is the best path to cost support.

## How Repatha compares to alternatives

Repatha's main competitor among PCSK9 inhibitors is Praluent (alirocumab), which has a similar mechanism and efficacy. Leqvio (inclisiran) offers twice-yearly dosing as an siRNA alternative. Compared with maximum-dose statins, Repatha provides an additional 50–70% LDL reduction. For patients who cannot tolerate statins, Repatha may be used as primary therapy. Generic statins and ezetimibe remain the usual first steps; Repatha is reserved for patients who cannot reach goal LDL with these agents.

## Monitoring and lifestyle

Lipid panels are checked 4–8 weeks after starting and periodically thereafter. Liver function tests are occasionally checked early in treatment. A heart-healthy diet, regular physical activity, smoking cessation, blood pressure control, and weight management all complement Repatha's LDL lowering. Attending follow-up appointments confirms whether your LDL goal is being met.

## What to expect from treatment

LDL-C reduction is detectable within 2–4 weeks of the first injection, with a maximum effect at approximately 4 weeks (for biweekly dosing) or 8 weeks (for monthly dosing). The FOURIER trial demonstrated that Repatha reduces cardiovascular events (heart attacks, strokes) by approximately 15% over about 2 years on top of statin therapy. Long-term use is required to maintain benefit.

## Before you start Repatha

A lipid panel, fasting glucose, and a review of all current medications are standard before starting. Discuss allergies, especially to any biologic medications, and inform your prescriber if you are pregnant or planning to become pregnant.

## Missed dose and overdose

If you miss a Repatha injection, administer it as soon as you remember if there are more than 7 days until your next scheduled dose. If fewer than 7 days remain, skip the missed dose and resume your regular schedule. If overdose is suspected, contact poison control or emergency services.

## Use in specific populations

Pregnancy: Use with caution — limited human data; the decision should be made with your clinician weighing cardiovascular risk. Breastfeeding: Unknown if evolocumab transfers to breast milk; consult your clinician. Older adults: No dose adjustment needed; efficacy and safety similar to younger adults. Renal/hepatic impairment: No dose adjustment required for mild-to-moderate impairment.

## When to contact your doctor

Contact your clinician if you develop signs of an allergic reaction (rash, itching, swelling, difficulty breathing), persistent injection-site reactions, or muscle pain (which may indicate a statin-related effect). Keep all lipid panel follow-up appointments.

## Storage and handling

Refrigerate at 2–8°C (36–46°F). Do not freeze. Allow to reach room temperature for 30 minutes before injecting. May be stored at room temperature up to 25°C for up to 30 days. Once removed from refrigeration, do not re-refrigerate. Keep out of reach of children.

## Clinical evidence and effectiveness

The FOURIER trial (27,564 patients with established cardiovascular disease on maximally tolerated statin therapy) showed that Repatha reduced the primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina) by 15% and MI by 27% compared with placebo. Long-term extensions confirm sustained LDL lowering and cardiovascular benefit with continued treatment. Repatha is now included in major cardiovascular guidelines as a preferred option for very-high-risk patients who cannot reach LDL goals on statins alone.

## Key takeaways

• Repatha is a PCSK9 inhibitor that lowers LDL-C by 50–70% on top of statin therapy.
• It reduces the risk of heart attacks and strokes in patients with established cardiovascular disease.
• Dosing options: 140 mg every 2 weeks or 420 mg once monthly.
• No generic is currently available; manufacturer programs offer significant savings.
• Regular lipid panel monitoring confirms the medicine is meeting your LDL goals.

## Medical disclaimer

This article about Repatha (evolocumab) is for general education and is not a substitute for professional medical advice, diagnosis, or treatment. Always follow the guidance of your physician or pharmacist and the instructions on your prescription label.